Wonbiogen Registers Wound Dressing Product with US FDA... "Expanding Export Opportunities"

[Asia Economy Reporter Hyunseok Yoo] One Biogen announced on the 7th that it has completed the registration of major wound dressing products such as hydrocolloids with the US FDA.

CEO Wonil Kim stated, “With this US FDA registration as the starting point, our export activities to North America will expand further, laying the foundation for future growth.”

One Biogen is currently negotiating supply contracts to launch exports of its wound dressing products to North America with US companies A and S.

In particular, discussions are underway with company A regarding all of its products, and with company M, headquartered in California, and company S in Los Angeles, it is promoting the supply of hydrocolloid spot products, liquid silicone dressing products for scar improvement, and functional cosmetics for acne to Amazon and premium retail stores.

Accordingly, One Biogen is expected to increase its export channels through new market entry into North America in the future.

Currently, One Biogen has been selected for the Alibaba entry project supported by the government and Gumi City, and is listed on the Alibaba B2B platform, which has 260 million buyers in 200 countries worldwide, receiving consulting from CK Bridge, an official Alibaba partner.

Additionally, it is negotiating exclusive export supply of hydrocolloid spot patches containing quantitatively extracted Centella Asiatica with company N, a pharmaceutical and cosmetics distribution company headquartered in Stockholm, Sweden.

Meanwhile, the sales proportion of the ‘hydrocolloid’ product line is increasing both domestically and internationally. The company plans to build a dedicated production plant at its headquarters. The second plant will establish new production facilities for medical device cosmetics and functional cosmetics, actively investing in new business areas.

CEO Wonil Kim said, “Overseas exports, which had been sluggish due to the COVID-19 pandemic, are gradually increasing. Major products such as medical device cosmetics and new products have completed supply contracts, and sales are scheduled to begin from the third quarter, leading to investments in related production facilities and a new dedicated hydrocolloid plant. Products like trouble care hydrocolloids and liquid spot patches are new markets where growth has just begun in the US and Europe, and we are making pre-investments in preparation for the increasing domestic and international order volumes in the future.”